Your browser doesn't support javascript.
loading
Incidence and Clearance of Anal Human Papillomavirus Infection in 16 164 Individuals, According to Human Immunodeficiency Virus Status, Sex, and Male Sexuality: An International Pooled Analysis of 34 Longitudinal Studies.
Wei, Feixue; Goodman, Marc T; Xia, Ningshao; Zhang, Jun; Giuliano, Anna R; D'Souza, Gypsyamber; Hessol, Nancy A; Schim van der Loeff, Maarten F; Dai, Jianghong; Neukam, Karin; de Pokomandy, Alexandra; Poynten, I Mary; Geskus, Ronald B; Burgos, Joaquin; Etienney, Isabelle; Moscicki, Anna-Barbara; Donà, Maria Gabriella; Gillison, Maura L; Nyitray, Alan G; Nowak, Rebecca G; Yunihastuti, Evy; Zou, Huachun; Hidalgo-Tenorio, Carmen; Phanuphak, Nittaya; Molina, Jean-Michel; Schofield, Alice M; Kerr, Stephen; Fan, Song; Lu, Yong; Ong, Jason J; Chikandiwa, Admire T; Teeraananchai, Sirinya; Squillace, Nicola; Wiley, Dorothy J; Palefsky, Joel M; Georges, Damien; Alberts, Catharina J; Clifford, Gary M.
Afiliação
  • Wei F; Early Detection, Prevention and Infections Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France.
  • Goodman MT; Cancer Prevention and Control Program, Cedars Cancer, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Xia N; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, China.
  • Zhang J; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, China.
  • Giuliano AR; Center for Immunization and Infection Research in Cancer (CIIRC), Moffitt Cancer Center, Tampa, Florida, USA.
  • D'Souza G; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
  • Hessol NA; Department of Clinical Pharmacy, University of California San Francisco, California, USA.
  • Schim van der Loeff MF; Department of Infectious Diseases, GGD Amsterdam, Amsterdam, Netherlands.
  • Dai J; School of Public Health, Xinjiang Medical University, Urumqi, Xinjiang, China.
  • Neukam K; Unidad Clínica de Enfermedades Infecciosas y Medicina Preventiva, UCEIMP, Instituto de Biomedicina de Sevilla, CSIC, Universidad de Sevilla, Hospital Universitario Virgen del Rocío, Seville, Spain.
  • de Pokomandy A; Chronic Viral Illness Service, McGill University Health Centre and Department of Family Medicine, McGill University, Montreal, Quebec, Canada.
  • Poynten IM; The Kirby Institute, University of New South Wales, Kensington, Sydney, New South Wales, Australia.
  • Geskus RB; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam.
  • Burgos J; Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.
  • Etienney I; Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • Moscicki AB; Vall d'Hebron Institut de Recerca (VHIR), Universitat Autónoma de Barcelona, Barcelona, Spain.
  • Donà MG; Proctology, Diaconesses-Croix Saint Simon Hospital, Paris, France.
  • Gillison ML; Department of Pediatrics, University of California, Los Angeles, California, USA.
  • Nyitray AG; Sexually Transmitted Infections (STI)/HIV Unit, San Gallicano Dermatological Institute IRCCS, Rome, Italy.
  • Nowak RG; Thoracic Head and Neck Medical Oncology Department, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Yunihastuti E; Center for AIDS Intervention Research and Clinical Cancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
  • Zou H; Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Hidalgo-Tenorio C; Faculty of Medicine Universitas Indonesia/Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
  • Phanuphak N; School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, China.
  • Molina JM; Kirby Institute, University of New South Wales, Sydney, Australia.
  • Schofield AM; Early Clinical Trial Unit. Biosanitary Institute (IBS.Granada). Infectious Diseases Unit. University Hospital Virgen de las Nieves, Granada, Spain.
  • Kerr S; Institute of HIV Research and Innovation, Bangkok, Thailand.
  • Fan S; Department of Infectious diseases, University of Paris Cité, St-Louis Hospital, Paris, France.
  • Lu Y; Institute of Cancer Sciences, The University of Manchester, Manchester, UK.
  • Ong JJ; HIV-NAT, Thai Red Cross AIDS Research Centre, and Research Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Chikandiwa AT; School of Public Health, Southwest Medical University, Luzhou, China.
  • Teeraananchai S; School of Public Health, the Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, Guizhou Medical University, Guiyang, China.
  • Squillace N; Central Clinical School, Monash University, Melbourne, Australia.
  • Wiley DJ; Wits RHI, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Palefsky JM; Department of Statistics, Faculty of Science, Kasetsart University, Bangkok, Thailand.
  • Georges D; Infectious Diseases Unit ASST-Monza, San Gerardo Hospital-University of Milano-Bicocca, Monza, Italy.
  • Alberts CJ; School of Nursing, University of California, Los Angeles, California, USA.
  • Clifford GM; Department of Medicine, University of California, San Francisco, California, USA.
Clin Infect Dis ; 76(3): e692-e701, 2023 02 08.
Article em En | MEDLINE | ID: mdl-35869839
ABSTRACT

BACKGROUND:

Understanding the natural history of anal high-risk human papillomavirus (hrHPV) infection is key for designing anal cancer prevention programs but has not been systematically characterized.

METHODS:

We reanalyzed data from 34 studies including 16 164 individuals in 6 risk groups defined by human immunodeficiency virus (HIV) status, sex, and male sexuality men who have sex with men (MSM) and people with HIV (MSMWH), HIV-negative MSM, women with HIV (WWH), HIV-negative women, men who have sex with women (MSW) with HIV (MSWWH), and HIV-negative MSW. We used Markov models to estimate incidence and clearance of 13 hrHPV types and their determinants.

RESULTS:

Human papillomavirus (HPV) 16 had the highest incidence-clearance ratio of the hrHPV types. MSMWH had the highest hrHPV incidence (eg, 15.5% newly HPV-16 infected within 2 years), followed by HIV-negative MSM (7.5%), WWH (6.6%), HIV-negative women (2.9%), MSWWH (1.7%), and HIV-negative MSW (0.7%). Determinants of HPV-16 incidence included HIV status and number of sexual partners for MSM, women, and MSW, and anal sex behavior for MSM only. HPV-16 clearance was lower for people with HIV (PWH) and lower for prevalent than incident infection. Among MSM, increasing age was associated with lower clearance of prevalent, but not incident, HPV-16 infection.

CONCLUSIONS:

This robust and unifying analysis of anal hrHPV natural history is essential to designing and predicting the impact of HPV vaccination and HPV-based screening programs on anal cancer prevention, particularly in MSM and PWH. Importantly, it demonstrates the higher carcinogenic potential of longstanding anal prevalent hrHPV infection than more recent incident infection.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças do Ânus / Neoplasias do Ânus / Infecções por HIV / Infecções por Papillomavirus / Minorias Sexuais e de Gênero Tipo de estudo: Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças do Ânus / Neoplasias do Ânus / Infecções por HIV / Infecções por Papillomavirus / Minorias Sexuais e de Gênero Tipo de estudo: Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article